Record Details

Histone deacetylase inhibitors in multiple myeloma

Hematology Reports

View Archive Info
 
 
Field Value
 
Authentication Code dc
 
Title Statement Histone deacetylase inhibitors in multiple myeloma
 
Added Entry - Uncontrolled Name Sarah Deleu
Eline Menu
Els Van Valckenborgh
Ben Van Camp
Joanna Fraczek
Isabelle Vande Broek
Vera Rogiers
Karin Vanderkerken
 
Uncontrolled Index Term Multiple myeloma; Epigenetics; HDAC inhibitors
 
Summary, etc. Novel drugs such as bortezomib and high dose chemotherapy combined with stem cell transplantation improved the outcome of multiple myeloma patients in the past decade. However, multiple myeloma often remains incurable due to the development of drug resistance governed by the bone marrow micro-environment. Therefore targeting new pathways to overcome this resistance is needed. Histone deacetylase (HDAC) inhibitors represent a new class of anti-myeloma agents. Inhibiting HDACs results in histone hyperacetylation and alterations in chromatine structure, which, in turn, cause growth arrest differentiation and/or apoptosis in several tumor cells. Here we summarize the molecular actions of HDACi as a single agent or in combination with other drugs in different in vitro and in vivo myeloma models and in (pre)clinical trials.
 
Publication, Distribution, Etc. PAGEPress Publications
2009-03-13
 
Electronic Location and Access application/pdf
text/html
http://www.pagepress.org/journals/index.php/hr/article/view/hr.2009.e9
 
Data Source Entry Hematology Reports; Vol 1, No 1 (2009); e9
 
Language Note en
 
Terms Governing Use and Reproduction Note <p>PAGEPress has chosen to apply the <a href="http://creativecommons.org/licenses/by-nc/3.0/" target="_blank">Creative Commons Attribution License</a> (CCAL) to all manuscripts to be published. </p> <p>An Open Access Publication is one that meets the following two conditions:</p> <ol><li>The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li><li>A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li></ol> Authors who publish with this journal agree to the following terms: 1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. 3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).